Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed or Refractory Multiple Myeloma: early-phase trial registry
4 of 11 indexed Relapsed or Refractory Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Relapsed or Refractory Multiple Myeloma: 11 US clinical trials tracked, 4 recruiting.
Relapsed or Refractory Multiple Myeloma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 4 of these trials.
Enrollment posture brief
Registry condition relapsed-or-refractory-multiple-myeloma
OPEN 4 | RECR 36% | LATE 4 | EARLY 7 | RANK #1577 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)
Relapsed or Refractory Multiple Myeloma lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed or Refractory Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed or Refractory Multiple Myeloma is recruiting below its size-band peers.
4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsed or Refractory Multiple Myeloma research.
Janssen Research & Development accounts for 4 of 11 trials (36.4%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Relapsed or Refractory Multiple Myeloma enrolment sits around 166 participants.
Median target enrolment is 166 among the 11 trials that report a genuine target (sentinel values excluded). 3 of those (27.3%) plan for fewer than 100 participants.
-
Relapsed or Refractory Multiple Myeloma research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene
NCT05519085
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development
NCT05652335
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX
NCT07116616
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co.
NCT06375044
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Janssen Research & Development
NCT05455320
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT05572515
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Bristol-Myers Squibb
NCT05552976
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT06425991
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
NCT01866293
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Sorrento Therapeutics
NCT03464916
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
Washington University School of Medicine
NCT00545519
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed or Refractory Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed or Refractory Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed or Refractory Multiple Myeloma page
11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Relapsed or Refractory Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Relapsed or Refractory Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed or Refractory Multiple Myeloma condition card totals 11 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.